Aaron Kesselheim (Scott Eisen/AP Images for AIDS Healthcare Foundation)

Har­vard’s Aaron Kessel­heim re­signs from ex­pert pan­el in wake of ad­u­canum­ab OK, blast­ing FDA for ‘worst drug ap­proval de­ci­sion in re­cent U.S. his­to­ry'

A third mem­ber of the FDA’s Pe­riph­er­al and Cen­tral Ner­vous Sys­tem Drugs Ad­vi­so­ry Com­mit­tee has re­signed in the wake of Bio­gen’s con­tro­ver­sial Aduhelm ap­proval, slam­ming the agency as he left and fur­ther deep­en­ing the con­tro­ver­sy sur­round­ing the de­ci­sion.

Har­vard Uni­ver­si­ty pro­fes­sor Aaron Kessel­heim quit in protest Thurs­day af­ter­noon, call­ing the Aduhelm OK “prob­a­bly the worst drug ap­proval de­ci­sion in re­cent U.S. his­to­ry.” Kessel­heim fol­lows both Joel Perl­mut­ter, a neu­rol­o­gist from Wash­ing­ton Uni­ver­si­ty in St. Louis, and David Knop­man, a neu­rol­o­gist from the Mayo Clin­ic, out the door.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.